Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: October 31, 2022 Report Code: GDGMDHC22388IDB-ST

Select Item

Cervical Cancer Drugs Market Report Overview

Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Its symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding, spotting between periods, and having longer or heavier (menstrual) periods than usual.

Key Targets Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 9, Vascular Endothelial Growth Factor Receptor 3, Transforming Growth Factor Beta, and Others
Key Mechanisms of Action Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Transforming Growth Factor Beta Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and Others
Key Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intramuscular, Intravenous Drip, Intratumor, Intradermal, Intralesional, Topical, and Others
Key Molecule Type Monoclonal Antibody, Small Molecule, Subunit Vaccine, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Fusion Protein, Recombinant Vector Vaccine, Vaccine, DNA Vaccine, and Others
Leading Companies AstraZeneca Plc, Agenus Inc, Bristol-Myers Squibb Co, Akeso Inc, Merck & Co Inc, Merck KGaA, Seagen Inc, TScan Therapeutics Inc, Advenchen Laboratories LLC, and BeiGene Ltd
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

The Cervical Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Cervical Cancer Pipeline Products Market Segmentation by Targets

The key targets in the Cervical Cancer pipeline products market are Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 9, Vascular Endothelial Growth Factor Receptor 3, Transforming Growth Factor Beta, and others.

Cervical Cancer Pipeline Products Market Analysis by Targets, 2022 (%)

Cervical Cancer Pipeline Products Market Analysis by Targets

For more target insights into the Cervical Cancer pipeline products market, download a free report sample

Cervical Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Cervical Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Vascular Endothelial Growth Factor A Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Transforming Growth Factor Beta Inhibitor, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, and others.

Cervical Cancer Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)

Cervical Cancer Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Cervical Cancer pipeline products market, download a free report sample

Cervical Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Cervical Cancer pipeline products market are intravenous, oral, parenteral, subcutaneous, intramuscular, intravenous drip, intratumor, intradermal, intralesional, topical, and others.

Cervical Cancer Pipeline Products Market Analysis by Routes of Administration, 2022 (%)

Cervical Cancer Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Cervical Cancer pipeline products market, download a free report sample

Cervical Cancer Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Cervical Cancer pipeline products market are monoclonal antibody, small molecule, subunit vaccine, cell therapy, gene-modified cell therapy, monoclonal antibody conjugated, fusion protein, recombinant vector vaccine, vaccine, DNA vaccine, and others.

Cervical Cancer Pipeline Products Market Analysis by Molecule Types, 2022 (%)

Cervical Cancer Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Cervical Cancer pipeline products market, download a free report sample

Cervical Cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Cervical Cancer pipeline products market are AstraZeneca Plc, Agenus Inc, Bristol-Myers Squibb Co, Akeso Inc, Merck & Co Inc, Merck KGaA, Seagen Inc, TScan Therapeutics Inc, Advenchen Laboratories LLC, and BeiGene Ltd.

Cervical Cancer Pipeline Products Market Analysis by Companies, 2022 (%)

Cervical Cancer Pipeline Products Market Analysis by Companies

To know more about the leading players in the Cervical Cancer pipeline products market, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Aadi Bioscience Inc
AbbVie Inc
Abivax SA
Acrivon Therapeutics Inc
ADC Therapeutics SA
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Aeterna Zentaris Inc
Affimed GmbH
Agenus Inc
Akeso Inc
Alkermes Plc
Alligator Bioscience AB
Almac Discovery Ltd
Alphamab Oncology
Alpine Immune Sciences Inc
amcure GmbH
Amgen Inc
Aminex Therapeutics Inc
Andes Biotechnologies
Anteris Technologies Ltd
AntiCancer Inc
Apimeds Inc
Apollomics Inc
Arcus Biosciences Inc
Ascendis Pharma AS
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aucentra Therapeutics Pty Ltd
Bayer AG
BeiGene Ltd
Beijing Corregene Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
Beijing Weiyuan Likang Biological Technology Co Ltd
Bio-Thera Solutions Ltd
BioAtla Inc
Biocad
BioIntegrator
Bioleaders Corp
Biomics Biotechnologies Co Ltd
BioNTech SE
Biotheus Inc
BioVaxys Technology Corp
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cellestia Biotech AG
Cellid Co Ltd
Cellular Biomedicine Group Ltd
Center for Genetic Engineering and Biotechnology
Centrymed Pharmaceutical Inc
Centus Biotherapeutics Ltd
Changchun Bcht Biotechnology Co Ltd
Chengdu Institute of Biological Products Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chineo Med Beijing Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Clovis Oncology Inc
Codiak BioSciences Inc
Coherent Biopharma
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Cue Biopharma Inc
Cullinan Oncology Inc
Curis Inc
CytomX Therapeutics Inc
CZ BioMed Corp
DAE HWA Pharmaceutical Co Ltd
Daewon Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Defence Therapeutics Inc
Disulfican Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
DynamiCure Biotechnology LLC
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Enara Bio Ltd
Enhancedbio Inc
Epygen Biotech Pvt Ltd
eTheRNA Immunotherapies NV
Etna Biotech Srl
Eubiologics Co Ltd
Exelixis Inc
EyeGene Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Flow Pharma Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
Gene Surgery
Genentech USA Inc
Genetic Immunity Inc
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Gilead Sciences Inc
GlycoNex Inc
GlyTR Therapeutics Inc
Gradalis Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Hamlet Pharma AB
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Hefei Ruichengsheng Biotechnology Co Ltd
HiFiBiO Therapeutics Inc
Hookipa Pharma Inc
Huabo Biopharm (Shanghai) Co Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
ImCheck Therapeutics SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
IMV Inc
Incyte Corp
Indaptus Therapeutics Inc
Inhibrx Inc
InnoMab Pte Ltd
Innovative Cellular Therapeutics Co Ltd
Innovene
Innovent Biologics Inc
Instil Bio Inc
Invectys SA
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Recbio Technology Co Ltd
Joint Biosciences Ltd
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Kintara Therapeutics Inc
Komipharm International Co Ltd
Kortuc Inc
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
LightOx Ltd
MacroGenics Inc
MaxiVAX SA
MedGene Therapeutics Inc
Medical Guidance Systems LLC
Medicenna Therapeutics Corp
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
MicroQuin Ltd
Midissia Therapeutics Inc
Molecular Partners AG
Morphogenesis Inc
Multitude therapeutics Inc
Mundipharma EDO GmbH
Mycenax Biotech Inc
Nanobiotix SA
Nanocan Therapeutics Corp
NanoMab Technology Ltd
Nektar Therapeutics
NeoTX Therapeutics Ltd
Netris Pharma SAS
Newish Technology Beijing Co Ltd
NextCure Inc
NGM Biopharmaceuticals Inc
Novartis AG
Novita Pharmaceuticals Inc
Nurix Therapeutics Inc
Nuvectis Pharma Inc
Nykode Therapeutics ASA
Obsidian Therapeutics Inc
Ocellaris Pharma Inc
Ology Bioservices Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Orgenesis Inc
Origincell Technology Group Co Ltd
Oxford Vacmedix UK Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Philogen SpA
Phoenix Life Sciences International Ltd
PI Therapeutics Ltd
Pionyr Immunotherapeutics Inc
Plus Therapeutics Inc
Precigen Inc
Precision Biologics Inc
Prelude Therapeutics Inc
Prestige BioPharma Ltd
Privo Technologies Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qingdao Sino-Cell Biomedicine Co Ltd
Quadriga BioSciences Inc
Qurient Co Ltd
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Relay Therapeutics Inc
RemeGen Co Ltd
Repertoire Immune Medicines Inc
Rizen (Suzhou) Biosciences Co Ltd
Rubius Therapeutics Inc
Salarius Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
Sanofi
Savoy Pharmaceuticals Inc
SCG Cell Therapy Pte Ltd
Seagen Inc
Sentan Pharma Inc
Seven and Eight Biopharmaceuticals Corp
Shandong New Time Pharmaceutical Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Gencells Therapeutics Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
Shantha Biotechnics Pvt Ltd
Shattuck Labs Inc
Sichuan Kelun Pharmaceutical Co Ltd
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
Sirnaomics Ltd
SK Bioscience Ltd
Sorrento Therapeutics Inc
SOTIO Biotech AS
SQZ Biotechnologies Co
Statera Biopharma Inc
Sumitomo Pharma Co Ltd
Shenghe (China) Biopharmaceutical Co Ltd
Suzhou BlueHorse Therapeutics Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Suzhou Stainwei Biotech Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Symphogen A/S
Synermore Biologics Co Ltd
Synthekine Inc
Systimmune Inc
T-Cure Bioscience Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
TargImmune Therapeutics AG
Tavotek Biotherapeutics
TCR Cure Biopharma Technology Co Ltd
Tevogen Bio Inc
Theravectys SA
Transcenta Holding Ltd
Transgene SA
Treadwell Therapeutics Inc
TScan Therapeutics Inc
Turnstone Biologics Inc
Up Therapeutics Inc
UTC Therapeutics Inc
Vaccitech Plc
Vascular Biogenics Ltd
Vectorite Biomedical Inc
Verastem Inc
Veru Inc
ViciniVax BV
Vincerx Pharma Inc
Vir Biotechnology Inc
Virion Therapeutics LLC
Virometix AG
VLP The Vaccines Company SL
VM Discovery Inc
Voltron Therapeutics Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Wuhan Binhui Biotechnology Co Ltd
Xencor Inc
Xiamen Innovax Biotech Co Ltd
Y-Biologics Inc
Zai Lab Ltd
Zeria Pharmaceutical Co Ltd
Zhejiang Yangshengtang Biotech Co Ltd
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cervical Cancer – Overview

Cervical Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cervical Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cervical Cancer – Companies Involved in Therapeutics Development

Cervical Cancer – Drug Profiles

Cervical Cancer – Dormant Projects

Cervical Cancer – Discontinued Products

Cervical Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the Cervical Cancer pipeline products market?

    The key targets in the Cervical Cancer pipeline products market are Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 9, Vascular Endothelial Growth Factor Receptor 3, Transforming Growth Factor Beta, and others.

  • What are the key mechanisms of action in the Cervical Cancer pipeline products market?

    The key mechanisms of action in the Cervical Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6,  Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and others.

  • What are the key routes of administration in the Cervical Cancer pipeline products market?

    The key routes of administration in the Cervical Cancer pipeline products market are intravenous, oral, parenteral, subcutaneous, intramuscular, intravenous drip, intratumor, intradermal, intralesional, topical, and others.

  • What are the key molecule types in the Cervical Cancer pipeline products market?

    The key molecule types in the Cervical Cancer pipeline products market are monoclonal antibody, small molecule, subunit vaccine, cell therapy, gene-modified cell therapy, monoclonal antibody conjugated, fusion protein, recombinant vector vaccine, vaccine, and DNA vaccine.

  • Which are the leading companies in the Cervical Cancer pipeline products market?

    Some of the leading companies in the Cervical Cancer pipeline products market are AstraZeneca Plc, Agenus Inc, Bristol-Myers Squibb Co, Akeso Inc, Merck & Co Inc, Merck KGaA, Seagen Inc, TScan Therapeutics Inc, Advenchen Laboratories LLC, and BeiGene Ltd.

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Pharmaceuticals
Merck & Co., Inc. - Digital Transformation Strategies
$1,495 | June 2023
Pharmaceuticals
Digital Marketing Trends in Severe Asthma
$1,950 | June 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more